Arindam Bose
About Arindam Bose
Arindam Bose is a seasoned biopharmaceutical executive currently serving as Vice President of Process Development at Akero Therapeutics and an advisor at Signet Healthcare Partners. He has extensive experience in the industry, including leadership roles at Pfizer and contributions to biosimilar strategies and biomanufacturing innovations.
Work at Akero Therapeutics
Arindam Bose serves as the Vice President of Process Development at Akero Therapeutics, a position he has held since 2019. His role involves overseeing the development processes for biopharmaceutical products. Akero Therapeutics focuses on developing treatments for liver diseases, and Bose's expertise contributes to the company's strategic initiatives in this area.
Current Roles and Advisory Positions
In addition to his role at Akero Therapeutics, Arindam Bose has been an Advisor at Signet Healthcare Partners since 2019. He also serves as a Member of the Board of Directors at Dyadic International, Inc. since 2016. These positions allow him to leverage his extensive experience in the biopharmaceutical sector to guide strategic decisions and foster innovation.
Experience at Pfizer Worldwide R&D
Bose worked at Pfizer Worldwide R&D from 2010 to 2016, where he held the position of Vice President for External Affairs and Biosimilars Strategy. His responsibilities included the development and execution of Pfizer's entry strategy for biosimilars, as well as managing competitive intelligence and external sourcing. He retired from Pfizer after a 34-year career in various leadership roles.
Education and Expertise
Arindam Bose holds a Doctor of Philosophy (Ph.D.) in chemical engineering from Purdue University, an M.S. from the University of Michigan College of Engineering, and a B. Tech from the Indian Institute of Technology, Kanpur. His educational background provides a strong foundation for his work in biopharmaceutical product development and regulatory strategy.
Achievements and Recognition
Bose has been recognized as a thought leader in the biopharmaceutical industry and was elected to the US National Academy of Engineering for his innovations in biomanufacturing. He has also served as chair of the Biologics and Biotechnology Leadership Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), highlighting his influence and contributions to the field.